Zynex revises Q4 2024 earnings guidance to $0.09 EPS, $53.6M revenue, and $0.20 FY 2024 EPS.

Zynex, a medical device company, has revised its Q4 2024 earnings guidance to an EPS of $0.09 and revenue of at least $53.6 million, slightly below analyst expectations. The FY 2024 EPS guidance is updated to $0.20. Recently, Director Joshua R. Disbrow bought 7,000 shares, while 52.13% of the stock is held by insiders. Zynex specializes in devices for pain management and muscle activation through electrical stimulation.

October 27, 2024
4 Articles

Further Reading